Journal of The Academy of Clinical Microbiologists

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  26 (2024)
Volume  25 (2023)
Volume  24 (2022)
Volume  23 (2021)
Volume  22 (2020)
Volume  21 (2019)
Volume  20 (2018)
Volume  19 (2017)
Volume  18 (2016)
Volume  17 (2015)
Volume  16 (2014)
Volume  15 (2013)
Related articles

VOLUME 17 , ISSUE 2 ( July-December, 2015 ) > List of Articles

Original Article

Urinary Candida isolates from a tertiary care hospital: Speciation and resistance patterns

Anita Singhal, Rajni Sharma, Vijay Laxmi Meena, Arun Chutani

Keywords : Antifungal susceptibility, Candida albicans, candiduria, non-albicans Candida

Citation Information : Singhal A, Sharma R, Meena VL, Chutani A. Urinary Candida isolates from a tertiary care hospital: Speciation and resistance patterns. 2015; 17 (2):100-105.

DOI: 10.4103/0972-1282.171891

License: CC BY-NC-SA 4.0

Published Online: 15-07-2024

Copyright Statement:  Copyright © 2015; Wolters Kluwer India Pvt. Ltd.


Abstract

Background: Candida species (spp.) is an integral member of the human microbiota and is an opportunistic pathogen. This pathogen infects the urinary tract both by ascending the urinary tract and by haematogenous spread. Aim: Speciation and antifungal susceptibility patterns of Candida isolates from urine specimens. Materials and Methods: Yeast-like isolates from urine culture were identified using a Mini-API® (bioMérieux, Marcy-l'Etoile, France) tool with ID 32 C strips (bioMérieux, Marcy-l'Etoile, France) for species identification and ATB Fungus 3 strips (bioMérieux, Marcy-l'Etoile, France) for susceptibility testing to five antifungal agents and results interpreted as per Centers for Disease Control and Prevention (CDC) guidelines. The significance of data was analysed using the chi-square test. Results: Candida spp. isolation was 10.2% (112/1092) and the commonest was Candida tropicalis [54.5% (61/112)], followed by C. glabrata 25% (28/112), and C. albicans, 11.6% (13/112). C. albicans showed good susceptibility to Flucytosine (100%) and Amphotericin B (84.6%) while non-albicans Candida susceptibility was only 82.9% and 60.6%, respectively. Conclusion: Non-albicans Candida have replaced Candida albicans as the more common causative agent. Resistance to both Amphotericin B and Fluconazole is on the rise, requiring the judicial use of antifungals in the immunocompetent and immunocompromised host as therapeutic and prophylactic therapy.

PDF Share
  1. da Silva EH, Ruiz Lda S, Matsumoto FE, Auler ME, Giudice MC, Moreira D, et al. Candiduria in a public hospital of São Paulo (1999-2004): Characteristics of the yeast isolates. Rev Inst Med Trop Sao Paulo 2007;49:349-53.
  2. Jang SK, Han HL, Lee SH, Ryu SY, Chaulagain BP, Moon YL, et al. PFGE-based epidemiological study of an outbreak of Candida tropicalis candiduria: The importance of medical waste as a reservoir of nosocomial infection. Jpn J Infect Dis 2005;58:263-7.
  3. Zarei Mahmoudabadi A, Keradmand AR, Enayatollahi N. Frequency of candiduria in inpatients and outpatients in department of Urology, Golestan Hospital, Ahvaz, Iran. Iran J Kid Dis 2009;3:114-5.
  4. Achkar JM, Fries BC. Candida infections of the genitourinary tract. Clin Microbiol Rev 2010;23:253-73.
  5. Jain N, Kohli R, Cook E, Gialanella P, Chang T, Fries BC. Biofilm formation by and antifungal susceptibility of Candida isolates from urine. Appl Environ Microbiol 2007;73: 1697-703.
  6. Griffith DP, Musher DM, Itin C. Urease: The primary cause of infection-induced urinary stones. Invest Urol 1976;13: 346-50.
  7. Klesper ME. Antifungal resistance among Candida species. Pharmacotherapy 2001;21:124s-32s.
  8. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in combined medical-surgical intensive care units in the United States. Infect Control Hosp Epidemiol 2000;21:510-5.
  9. Vidigal PG, Santos SA, Fernandez MA, Bonfim PS, Martinez HV, Svidzinski TE. Candiduria by Candida tropicalis evolves to fatal candidemia. Medical Case Studies 2011;2:22-5.
  10. Knoke M, Bernhardt H, Schulz K, Schröder G, Zimmermann K. Funguria and Candida-specific immunoglobulins in patients with systemic candidosis. Mycoses 2000;43:145-9.
  11. Pfaller MA, Castanheira M, Messer SA, Moet GJ, Jones RN. Echinocandin and triazole antifungal susceptibity profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigates: Application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). Diagn Micobiol Inf Dis 2011;69:45-50.
  12. Chapeland-Leclerc F, Hennequin C, Papon N, Noël T, Girard A, Socié G, et al. Acquisition of Flucytosine, Azole, and Caspofungin Resistance in Candida glabrate bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient. Antimicrob Agents Chemother 2010;54:1360-2.
  13. R Y, M P S, U A B, R R, K B A. Candiduria: Prevalence and trends in antifungal susceptibility in a tertiary care hospital of Mangalore. J Clin Diagn Res 2013;7:2459-61.
  14. Kashid RA, Belawadi S, Devi G, Indumati. Incidence of non-candida Albicans in patients with urinary tract infection with special reference to speciation and antifungal susceptibility. J Evol Med Dent Sci 2012;1:572-7.
  15. Dharwad S, Saldanha Dominic RM. Species identification of Candida isolates in various clinical specimens with their antifungal susceptibility patterns. J Clin Diagn Res 2011;5(Suppl 1):1177-81.
  16. Zarei-Mahmoudabadi A, Zarrin M, Ghanatir F, Vazirianzadeh B. Candiduria in hospitalized patients in teaching hospitals of Ahvaz. Iran J Microbiol 2012;4:198-203.
  17. Kauffman CA. Candiduria. Clin Infect Dis 2005;41(Suppl 6): S371-6.
  18. Behiry IK, El Hedeki SK, Mahfouz M. Candida infection associated with urinary catheter in critically ill patients. Identification, antifungal susceptibility and risk factors. Res J Med Med Sci 2010;5:79-86.
  19. Bukhary ZA. Candiduria: A review of clinical significance and management. Saudi J Kidney Dis Transpl 2008;19: 350-60.
  20. Nguyen MH, Peacock JE Jr, Morris AJ, Tanner DC, Nguyen ML, Snydman DR, et al. The changing face of candidaemia: The emergence of the non-Candida albicans species and antifungal resistance. Am J Med 1996;100:617-23.
  21. Jain M, Dogra V, Mishra B, Thakur A, Loomba PS, Bhargava A. Candiduria in catheterized intensive care unit patients: Emerging microbiological trends. Indian J Pathol Microbiol 2011;54:552-5.
  22. Colombo AL, Guimarães T. Candiduria: The clinical and therapeutic approach. Rev Soc Bras Med Trop 2007;40: 332-7.
  23. Prasad KN, Agarwal J, Dixit AK, Tiwari DP, Dhole TN, Ayyagari A. Role of yeasts as nosocomial pathogens & their susceptibility to Fluconazole & Amphotericin B. Indian J Med Res 1999;110:11-7.
  24. Pfaller MA, Espinel-Ingroff A, Canton E, Castanheira M, Cuenca-Estrella M, Diekema DJ, et al. Wild-Type MIC distributions and epidemiological cutoff values for Amphotericin B, Flucytosine, and Itraconazole and Candida spp. as determined by CLSI broth microdilution. J Clin Microbiol 2012;50:2040-6.
  25. Mahmoudabadi AZ, Zarrin M, Fard MB. Antifungal susceptibility of Candida Species isolated from candiduria. Jundisha-pur J Microbiol 2013;6:24-8.
  26. Pfaller MA, Diekema DJ, Messer SA, Hollis RJ, Jones RN. In vitro activities of Caspofungin compared with those of Fluconazole and Itraconazole against 3,959 clinical isolates of Candida spp., including 157 Fluconazole-resistant isolates. Antimicrob Agents Chemother 2003;47:1068-71.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.